An interventional study of Low-Intensity Focused Ultrasound Stimulation and Sham Low-Intensity Focused Ultrasound Stimulation in Chronic Migraine Headache, sponsored by Chinese PLA General Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Chinese PLA General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.
Among the 80 studies in Migraine Disorders with a site in China, this one is the 57th largest by planned enrollment of the 61 interventional ones that give a count, is one of 10 that started in 2026, is one of 21 with no phase, reaches primary completion later than 26 of the 39 other live ones, and was the 78th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:
Brise Pharmaceuticals Co., Ltd. · Sites in China
Ages 18+
Pfizer · Sites in China, United States, Israel and 1 more country
Ages 18+
Pfizer · Sites in China, United States, Israel
Ages 18+
Sichuan Purity Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18–75
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18–60
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 25 · Phase 4 7
First in 2007; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 288 across the 61 interventional studies, 330 across the 19 observational. Of the 29 that completed or were terminated, 10 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 80 have an industry lead sponsor. The 10 most frequent:
Chinese PLA General Hospital is the lead sponsor of 574 studies on the registry; 209 are open to participants now.
Chinese PLA General Hospital has 5 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
9 of the studies in Migraine Disorders with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07347028Beijing Tiantan HospitalClinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Knee Osteoarthritis(OA) | 2026-12-01 |
| NCT07347067Beijing Tiantan HospitalClinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Chronic Migraine | 2026-12-01 |
| NCT06347276China National Center for Cardiovascular DiseasesCerebral Microembolization Associated With PFO Closure | 2026-12-31 |
| NCT06953622Peking University Third HospitalEstablishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 80 studies in Migraine Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic migraine is a disabling neurological disorder characterized by frequent headache attacks and significant impairment of quality of life. Low-intensity focused ultrasound (LIFUS) is a non-invasive neuromodulation technique that can precisely target deep brain regions. This study aims to evaluate the efficacy, safety, and tolerability of LIFUS targeting the left dorsolateral prefrontal cortex (DLPFC) for preventive treatment of chronic migraine in adults.
This is a randomized, single-blind, sham-controlled clinical trial. Eligible participants with chronic migraine will be randomly assigned to receive either active LIFUS stimulation targeting the left DLPFC or sham stimulation. Participants will receive 10 stimulation sessions over 2 weeks and will be followed for 3 months after intervention.
The primary outcome is the change in monthly migraine days from baseline to 1 month after intervention. Secondary and exploratory outcomes include headache-related disability, quality of life, psychological assessments, electrophysiological measurements, neuroimaging changes, and safety outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Low-Intensity Focused Ultrasound Stimulation
Device: Sham Low-Intensity Focused Ultrasound Stimulation
Participants receive active low-intensity focused ultrasound stimulation targeting the left dorsolateral prefrontal cortex (DLPFC) for preventive treatment of chronic migraine.
Participants undergo sham stimulation procedures with identical positioning, coupling, and treatment duration as the active stimulation group, but without effective ultrasound output.
Change in Monthly Migraine Days
Change in monthly migraine days from baseline after intervention.
Time frame: Baseline and 1 month after intervention
Change in Acute Headache Medication Days
Change in the number of days using acute headache medications from baseline to 1 month after intervention.
Time frame: Baseline and 1 month after intervention
50% Responder Rate Based on Monthly Migraine Days
Proportion of participants achieving at least 50% reduction in monthly migraine days compared with baseline.
Time frame: 1 month after intervention
75% Responder Rate Based on Monthly Migraine Days
Proportion of participants achieving at least 75% reduction in monthly migraine days compared with baseline.
Time frame: 1 month after intervention
Change in Moderate/Severe Headache Days
Change in the number of moderate or severe headache days from baseline to 1 month after intervention.
Time frame: Baseline and 1 month after intervention
Change in Visual Analog Scale (VAS) Score for Headache Intensity
Headache intensity is assessed using the Visual Analog Scale (VAS). Scores range from 0 to 10, with higher scores indicating greater headache intensity.
Time frame: Immediately after each intervention session to 1 month after intervention
Change in Most Bothersome Migraine Symptom (MBS) Improvement Score
Participants identify their most bothersome migraine-associated symptom at baseline from nausea, vomiting, photophobia, or phonophobia. The same symptom is assessed during follow-up using a 7-point patient-reported improvement scale ranging from very much improved to very much worse.
Time frame: Immediately after intervention and 1 month after intervention
Change in monthly Migraine Disability Assessment (mMIDAS) Score
The monthly Migraine Disability Assessment (mMIDAS) questionnaire assesses migraine-related disability during the previous month. Higher scores indicate greater migraine-related disability.
Time frame: Baseline, immediately after intervention, and 1 month after intervention
Change in Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Score
Time frame: Baseline, immediately after intervention, and 1 month after intervention
Change in Headache Impact Test-6 (HIT-6) Score
The 6-item Headache Impact Test (HIT-6) assesses the impact of headache on daily functioning. Total scores range from 36 to 78, with higher scores indicating greater headache impact.
Time frame: Baseline, immediately after intervention, and 1 month after intervention
Patient Global Impression of Change (PGI-C) Score
The Patient Global Impression of Change (PGI-C) is a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), with higher scores indicating less favorable perceived change.
Time frame: Immediately after intervention and 1 month after intervention
Change in Generalized Anxiety Disorder 7-item (GAD-7) Score
The Generalized Anxiety Disorder 7-item (GAD-7) scale assesses anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating greater anxiety symptom severity.
Time frame: Baseline, immediately after intervention, and 1 month after intervention
Change in Patient Health Questionnaire-9 (PHQ-9) Score
The Patient Health Questionnaire-9 (PHQ-9) assesses depressive symptoms. Total scores range from 0 to 27, with higher scores indicating greater depressive symptom severity.
Time frame: Baseline, immediately after intervention, and 1 month after intervention
Incidence of Adverse Events
Number and proportion of participants who experience one or more adverse events during the study. All observed and spontaneously reported adverse events will be recorded regardless of their relationship to the study intervention; severity and relatedness will also be assessed.
Time frame: From baseline through completion of the 3-month follow-up visit
Number of Participants with New Abnormal Findings on T2-Weighted MRI
Number of participants with new brain parenchymal signal abnormalities, hemorrhage, or edema identified on T2-weighted MRI within 24 hours after the final intervention compared with baseline.
Time frame: Baseline and within 24 hours after the final intervention session
Long-term Change in Monthly Acute Headache Medication Days
Change in the number of days using acute headache medications compared with baseline during extended follow-up
Time frame: 2 and 3 months after intervention
Long-term Migraine Responder Rate (≥50%)
Proportion of participants achieving at least 50% reduction in monthly migraine days compared with baseline during extended follow-up.
Time frame: 2 and 3 months after intervention
Long-term Change in Moderate/Severe Headache Days
Change in monthly moderate/severe headache days compared with baseline during extended follow-up.
Time frame: 2 and 3 months after intervention
Long-term Change in Migraine Disability (mMIDAS)
Change in monthly Migraine Disability Assessment (mMIDAS) score compared with baseline during extended follow-up.
Time frame: 2 and 3 months after intervention
Long-term Change in Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Score
Change in migraine-specific quality of life assessed using the MSQ v2.1 questionnaire compared with baseline during extended follow-up.
Time frame: 2 and 3 months after intervention
Long-term Change in Headache Impact Test-6 (HIT-6) Score
Change in headache-related impact assessed using the HIT-6 questionnaire compared with baseline during extended follow-up.
Time frame: 2 and 3 months after intervention
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.
Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 14 months is below that.
Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese PLA General Hospital →